Atrium Therapeutics, Inc.
RNA
$13.19
$0.413.21%
NASDAQ
| 03/31/2026 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Net Income | 42.91% | 35.29% | |||
| Total Depreciation and Amortization | 23.77% | -8.62% | |||
| Total Amortization of Deferred Charges | -- | -- | |||
| Total Other Non-Cash Items | 226.19% | -80.28% | |||
| Change in Net Operating Assets | -581.16% | -54.01% | |||
| Cash from Operations | -61.77% | -34.37% | |||
| Capital Expenditure | -138.68% | -- | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -- | -- | |||
| Cash from Investing | -138.68% | -- | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | -- | -- | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | 1,397.71% | 30.92% | |||
| Cash from Financing | 1,397.71% | 30.92% | |||
| Foreign Exchange rate Adjustments | -- | -- | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | -- | -- | |||